Objective: To examine the association between obesity and serum and ultrasound measures of ovarian reserve in late reproductive age women.
R eproductive aging is characterized by the depletion of a relatively fixed number of ovarian follicles during a woman_s lifetime. 1, 2 Clinically, reproductive aging results in infertility, increased risk of miscarriage, menopausal symptoms, and ultimately menopause. Ovarian reserve represents the quantity and quality of the remaining ovarian follicle pool. Although multiple serum and ultrasound measures have been found to reflect ovarian reserve and are used clinically to assess reproductive status, a limited amount of data is available on whether body size affects these measures.
In natural ovarian aging, the following measures of ovarian reserve have been studied: antimullerian hormone (AMH), inhibin B, follicle-stimulating hormone (FSH), estradiol, and antral follicle count (AFC). AMH, also known as müllerianinhibiting substance, is a glycoprotein produced by granulosa cells surrounding ovarian follicles. 3 Because the majority of AMH is secreted by primary and preantral follicles, levels are gonadotropin independent and are therefore a more consistent measure of ovarian reserve than other hormones such as FSH. 4, 5 Low AMH has been associated with natural ovarian aging and infertility. 6<8 Inhibin B is a heterodimeric glycoprotein produced by small antral follicles in the ovary. 9 Inhibin B provides negative feedback to FSH secretion from the pituitary and is highest during the follicular phase. 9 In healthy women, inhibin B levels decrease during reproductive life and the menopausal transition. 10 AFC is an ultrasound marker of ovarian aging. 11 With reproductive aging, the primordial follicle pool decreases. Although the size of the primordial follicle pool is difficult to measure directly, it is correlated with the number of growing follicles. 12, 13 These growing follicles can then be visualized using ultrasonography. In the assisted reproductive technology literature, a lower AFC has been associated with poor ovarian response. 14, 15 Various cut points for a low AFC, most often less than 4 or 6, have been described in predicting poor ovarian response. 15 Recently, we reported that AMH and inhibin B were negatively associated with body size in a cohort of late reproductive age women. 16, 17 There are two possible explanations for the observed negative effect of body mass index (BMI) on AMH and inhibin B. First, lower levels of AMH and inhibin B in overweight and obese women may reflect a decrease in ovarian reserve. This first explanation is supported by the observation that obese women are less fertile (even in the presence of ovulatory menstrual cycles) and more prone to miscarriage than normal weight women. 18<20 In addition, obese women exhibit decreased ovarian response to gonadotropin stimulation during superovulation. 21, 22 Second, obesity may affect ovarian hormonal production, sequestration, or clearance. 23, 24 The overall goal of this study was to further examine the association between obesity and measures of ovarian reserve in late reproductive age women. Our primary objective was to assess whether the AFC, an ultrasound marker of ovarian reserve, varies by body size. We hypothesized that if obesity leads to decreased ovarian reserve, then the AFC would be lower in obese women than in normal weight women. Our secondary objective was to test whether other hormonal measures of ovarian reserve (AMH, inhibin B, FSH, and estradiol) vary by body size in this sample of late reproductive age women.
MATERIALS AND METHODS Study participants
Thirty-six late reproductive age women were recruited from the Philadelphia area. Twenty-two women are participants of the Penn Ovarian Aging Study, an ongoing population-based cohort. These women were a separate sample from our previous reports on the associations among AMH, inhibin, and obesity, and all data were collected specifically for this study. Eighteen women had a normal BMI (G25 kg/m 2 ), and 18 women were in the obese group (Q30 kg/m 2 ). Inclusion criteria included age older than 40 years, menstrual cycles in the normal range (22/35 days), BMI less than 25 kg/m 2 or 30 kg/m 2 or more, and intact uterus and ovaries. Exclusion criteria included hormone therapy, contraception, and polycystic ovarian syndrome. The women were generally healthy. Several women were being treated for the following comorbidities: hypertension (n = 5), hypercholesterolemia (n = 2), hypothyroidism (n = 2), nonYinsulin-dependent diabetes mellitus (n = 1), and history of breast cancer and taking tamoxifen (n = 1). The study was approved by the institutional review board of the University of Pennsylvania. All women provided written consent.
Measures
The women underwent a nonfasting blood draw, anthropometric measurements, and a transvaginal pelvic ultrasound scan within the first 4 days of a menstrual cycle. Height (without shoes) was measured to the nearest 0.5 cm with a vertical ruler. Body weight (in light clothing) was measured to the nearest 0.2 kg with a portable scale. Blood samples were centrifuged and frozen in aliquots at j80-C. FSH, estradiol, inhibin B, and AMH assays were conducted in the General Clinical Research Center of the University of Pennsylvania. For each sample, hormonal assays were performed in duplicate; the means of the duplicates were used for analysis. Estradiol and FSH were measured by radioimmunoassay using Coat-A-Count commercial kits (Diagnostic Products, Los Angeles, CA). The intra-and interassay coefficients of variation were less than 5%. The lower limit of detection for estradiol was 20 pg/mL. The lower limit of detection for FSH was 0.06 mIU/mL. AMH was assayed using AMH enzymelinked immunosorbent assay kits (Diagnostic Systems, Webster, TX). The intra-and interassay coefficients of variation were less than 4% and 6%, respectively. The lower limit of detection was 0.05 ng/mL. Dimeric inhibin B was assayed using inhibin B enzyme-linked immunosorbent assay kits (Diagnostic Systems). The intra-and interassay coefficients of variation were 3.5% to 4.6% and 6.3% to 7.6%, respectively. The lower limit of detection was 7 pg/mL. All values used in statistical analyses were actual values, even those below the kit threshold of detection.
BMI was calculated by weight (in kilograms) divided by the square of height (in meters). BMI was dichotomized into normal weight (G25 kg/m 2 ) or obese (Q30 kg/m 2 ) groups as selected for the study.
Ovarian volume and AFCs were determined by transvaginal pelvic ultrasonography within the first 4 days of a menstrual cycle. Pelvic ultrasound scans were performed primarily by two trained gynecologists using a standard protocol. Both ovaries were measured in the maximal transverse, anteroposterior, and longitudinal diameters. The volume was estimated as P/6 Â 3 diameters. Abnormalities of morphology were collected. Antral follicles were defined as follicles between 2 and 10 millimeters in diameter. The AFC represents the total number of antral follicles from two ovaries. Age, race, smoking status, and alcohol use data were collected through a structured questionnaire by self-report at the time of the ultrasound scan as potential confounders of the association between body size and measures of ovarian reserve.
Power calculation
Estimates of statistical power to detect a difference in the AFC between obese and normal weight women were conducted. A low AFC was defined as follicle count fewer than 4. The prevalence of a low AFC in normal weight women was assumed to be 50%. Type I error was set at 5%. In a 1:1 ratio of obese to normal weight women, a total of 30 women were required to have 80% power to detect a relative risk of 2 when comparing the proportion of obese women with the proportion of normal weight women with an AFC fewer than 4. A post hoc power calculation determined that this study had 86% power to detect the observed difference, which corresponds to an effect size of 0.88 SD units or greater between mean AFCs in the two groups.
Statistical methods
Baseline characteristics were compared between the normal weight and obese groups. A Student t-test (for normally distributed data) or Wilcoxon rank-sum test (for nonnormally distributed variables) was used to compare continuous variables. Categorical variables were characterized by proportions and compared by a W 2 test. Graphic displays of outcome variables were explored to determine data distributions. Hormone measures were transformed to natural log values to minimize the impact of their skewed distributions. Mean values for hormones are reported as geometric means. Two-sample t-tests were performed to compare mean log-transformed hormonal values between the two weight groups. Ovarian volume and AFCs were compared between the two groups using the t or W 2 test as appropriate for the data. Correlations between hormone values and ultrasound measurements were also computed. Finally, multivariable linear regression models were constructed to examine the independent associations of AMH, inhibin B, and AFC with BMI, adjusting for other potential confounders. A two-tailed P value of G0.05 was considered statistically significant. Table 1 . The mean age (T SD) was 45 T 2.0 years. The mean BMI (95% confidence interval [CI]) was 22.4 (21.6/23.2) in normal weight women and 37.6 (34.2/40.8) in obese women. All variables except age significantly differed between the two groups.
RESULTS

Demographic characteristics are shown in
The mean AFC, the primary outcome, was similar between the two groups ( Table 2 ). Using a cut point of 4 for a low AFC, the proportion of normal weight women (17%) and the proportion of obese women with a low AFC (22%) were similar (P = 0.80). The relative risk of a low AFC in obese compared with normal weight women was 1.33 (0.35/5.13). Results were similar using cut points of 3 or 5 for a low AFC. The proportion of women with ovarian cysts was high (44%) but comparable between the groups. Ovarian volume was not significantly higher in the obese group when compared with normal weight (P = 0.06).
Hormone measures of ovarian reserve by BMI group are depicted in Table 2 . AMH and inhibin B were significantly lower in obese women. FSH and estradiol were similar in the two groups.
We then examined the adjusted associations between clinically and statistically significant study variables with AMH and inhibin B in linear regression models. BMI (P = 0.02) and age (P = 0.003) remained independent predictors of AMH in a multivariable model also adjusted for smoking, alcohol, and race ( Table 3 ). The adjusted geometric mean AMH levels were lower in obese women compared with normal weight women, 0.06 ng/mL (95% CI: 0.03/0.13) and 0.28 ng/mL (95% CI: 0.12/0.67), respectively. Smoking (P = 0.26), alcohol (P = 0.43), and race (P = 0.71) were not significantly associated with AMH in the model. BMI (P = 0.08) was not independently associated with inhibin B in a multivariable model that included age, smoking, alcohol, and race ( Table 3 ). The adjusted geometric mean inhibin B levels seemed lower in obese women compared with normal weight women (9.5 [8.0/11.3] ng/mL and 12.5 [10.1/15.4] ng/mL respectively), but this finding did not reach statistical significance. Age (P = 0.2), smoking (P = 0.82), alcohol (P = 0.89), and race (P = 0.39) were not significantly associated with inhibin B. In both AMH and inhibin B models, we also tested the interaction between the AFC and BMI and found no statistical significance. Finally, AMH and inhibin B models excluding the woman taking tamoxifen showed no change in the association between each hormone and BMI.
DISCUSSION
The overall goal of this study was to investigate whether measures of ovarian reserve differed between obese and normal weight women in late reproductive age. Specifically, we conducted a comprehensive evaluation of measures of ovarian reserve, including both serum and ultrasound measures. We hypothesized that all measures of ovarian reserve would be affected by body size. We found that mean AMH levels were significantly lower in obese women compared with normal weight women but that other hormone measures and ultrasound measures did not differ by body size. 16, 17 To our knowledge, this study is the first to examine AFC and body size in late reproductive age women. These findings do not support the notion that ovarian reserve is impaired in obese women.
Although the AFC was slightly lower and ovarian volume seemed clinically larger in obese women compared with normal weight women, the differences were not statistically significant. Given the small sample size, mean ovarian volumes could be influenced by the presence of outliers, as evidenced by wide CIs. Similar proportions of the groups had ovarian cysts; therefore, the presence of cysts did not confound the association. Because most ovarian cysts were measured in two dimensions, we were unable to subtract ovarian cyst volume from total ovarian volume for more detailed analysis. However, because several volumes were affected by large cysts, subtracting the cyst volumes would have likely resulted in more similar ovarian volumes between the two weight groups.
Our examination of AFC with other hormone measures of ovarian reserve showed that AFC had a significant, positive association with AMH. However, AFC was not associated with inhibin B. This finding suggests that AFC and AMH both reflect the pool of early, gonadotropin-independent follicles. In contrast, inhibin B is secreted from gonadotropindependent, recruited follicles and may be a less consistent measure of the ovarian reserve pool.
Taken together, these results indicate that decreased ovarian reserve is not the direct cause of lower AMH in obese, regularly cycling, late reproductive age women. In published data, serum and ovarian measures of decreased ovarian reserve do not show consistent changes with body size. 17,25/27 One explanation for this lack of consistency is that these measures are not ideal surrogates of ovarian reserve. Alternatively, body size may alter hormone production at the level of the ovary and increase sequestration or elimination of serum hormones. 23, 24, 28 For example, the observation that adiponectin modulates ovarian steroidogenesis in conjunction with insulin and gonadotropins provides indirect evidence that obesity alters ovarian hormonal synthesis. 28 Several limitations to our study should be considered. As observed in the general population, race and BMI were highly associated with one another in this study, limiting the ability to separate the effect of the two variables on the ovarian reserve measures. It is not clear whether this affects the validity of our results. Data on racial differences in ovarian reserve measures are mixed. Although the Study of Women_s Health Across the Nation has reported higher FSH in African American women compared with white women, we have not observed this difference in the Penn Ovarian Aging cohort. 16, 17, 29 Therefore, in this study, we did not recruit participants or stratify statistical analyses based on race.
Antral follicles 2 to 10 mm in size can be difficult to visualize with increased body size. Had this occurred, it would have biased the results toward finding a difference in the AFC between the two BMI groups. In addition, using surrogate markers to measure ovarian aging in late reproductive age women is another potential limitation. Ideal surrogate markers are closely linked with the clinical outcome of interest. In younger patients, these surrogate hormonal and ultrasound measures of ovarian reserve have been validated using assisted reproductive technology outcomes. 30 However, in late reproductive age women, the association of these measures with the gold standard measurement of time to menopause has not been established. Another limitation is the cross-sectional design, in which risk factors (BMI) and outcomes of interest are examined at one time point. Therefore, causality, or the sequence of events, cannot be determined. Nonetheless, it is biologically plausible that body fat contributes to different levels of AMH.
Study participants had several comorbidities representative of women in this age group. By including these women, our findings are potentially more generalizable. One woman had a history of breast cancer and was receiving tamoxifen. Because of the potential effect of tamoxifen on hormonal measures of ovarian reserve, analyses were rerun excluding this woman. 31 No significant departures from our reported results were observed.
Finally, although this pilot study had small numbers, it was sufficiently powered for our outcome of interest. Because we sampled women by BMI, difference in demographics, such as smoking and race, arose by chance. However, the association of BMI with AMH persisted when we adjusted for these potential confounders, an indication that our findings are robust. Unfortunately, although mean inhibin B levels appeared lower in obese women than in normal weight women after adjustment, the association was no longer statistically significant in this limited sample.
CONCLUSIONS
In conclusion, we present the first report on the relationship between body size and ovarian AFC. Although certain hormone measures such as AMH are decreased in obese women, ultrasound measures of ovarian reserve do not differ by body size. Therefore, it does not seem that obese women have decreased ovarian reserve compared with normal weight women. These findings may be a function of different hormone metabolism, sequestration, or clearance in obese women. Further studies of the mechanisms underlying these observations are warranted. Importantly, given the increased use of these hormone measures in clinical practice, clinicians should be aware that levels may be altered in obese women. Serum measures of ovarian reserve, especially inhibin B and AMH, should be interpreted with caution in these women.
